Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Evaluation of the clinical ben...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients - Permal study sub-set analysis

Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients - Permal study sub-set analysis

Show other versions (3)
Bibliographic Details
Main Authors: Debruyne, F, Boyle, P, Vela-Navarrete, R, Da Silva, F, Teillac, P, Perrin, P, Hamdy, F, Raynaud, J
Format: Conference item
Published: 2004
  • Holdings
  • Description
  • Other Versions (3)
  • Similar Items
  • Staff View

Similar Items

  • Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis.
    by: Debruyne, F, et al.
    Published: (2004)
  • [Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis].
    by: Debruyne, F, et al.
    Published: (2004)
  • Evaluation of the clinical benefit of permixon® and tamsulosin in severe BPH patients - PERMAL study subset analysis
    by: Debruyne, F, et al.
    Published: (2004)
  • Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study
    by: Debruyne, F, et al.
    Published: (2002)
  • Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study.
    by: Debruyne, F, et al.
    Published: (2002)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs